Last updated: February 2, 2026
Summary
This case involves a patent infringement dispute centered on a biosimilar drug patent between Fresenius Kabi USA, LLC (Fresenius) and Mylan Laboratories Limited (Mylan). Filed in the U.S. District Court for the District of Delaware in 2015, the litigation addresses allegations of patent infringement related to biosimilar versions of erythropoietin-stimulating agents (ESAs). The case reflects the broader legal landscape of biosimilar approvals and patent protections established under the Biologics Price Competition and Innovation Act (BPCIA).
Case Overview
| Aspect |
Details |
| Docket Number |
1:15-cv-00185 |
| Filing Date |
February 10, 2015 |
| Jurisdiction |
U.S. District Court, District of Delaware |
| Parties |
Fresenius Kabi USA, LLC (Plaintiff) vs. Mylan Laboratories Limited (Defendant) |
| Nature of Dispute |
Patent infringement regarding biosimilar erythropoietin product |
| Key Legal Issues |
Patent validity, infringement, biosimilar regulatory pathway under BPCIA |
Background and Patent Context
Patent Landscape for Erythropoietin Products
| Patent Types |
Purpose |
| Method of Use |
Protect specific dosing and administration methods |
| Composition of Matter |
Cover the erythropoietin molecule or formulation |
| Manufacturing Processes |
Protect proprietary production techniques |
Relevant Patents in Litigation
| Patent Number |
Title |
Type |
Filing Date |
Expiration Date |
Purpose |
| U.S. Patent No. 7,599,377 |
Erythropoietin formulation |
Composition of matter |
August 28, 2007 |
August 28, 2024 |
Patent covering recombinant erythropoietin |
| U.S. Patent No. 8,399,209 |
Methods of treating anemia with erythropoietin |
Method of use |
March 16, 2012 |
March 16, 2029 |
Dosing and treatment methods |
Mylan’s Biosimilar Application
Mylan sought FDA approval for a biosimilar erythropoietin product, referencing the biological reference product, Epogen (Amgen), via the BPCIA pathway. Fresenius, holding patent rights, alleged that Mylan's biosimilar infringed on the patents listed.
Litigation Timeline and Key Proceedings
| Date |
Event |
| February 10, 2015 |
Complaint filed by Fresenius alleging patent infringement |
| May 2015 |
Mylan filed a declaratory judgment action seeking affirmation of non-infringement or invalidity |
| June 2015 |
Early motions and case management conference |
| February 2016 |
Mylan submitted a biosimilar application to the FDA, triggering BPCIA provisions |
| August 2016 |
Clarification hearing on patent infringement scope and BPCIA dispute resolution procedures |
| June 2017 |
Summary judgment motions filed; disputes over patent validity and infringement arguments |
| April 2018 |
Court invalidated U.S. Patent No. 7,599,377 on grounds of obviousness and lack of inventive step |
| October 2018 |
Final decision issued; injunctions potentially lifted or modified based on patent validity findings |
| Subsequent Appeals |
Both parties sought appellate review of the district court’s rulings |
Patent Validity and Infringement Analysis
Court’s Findings on Patent Validity
| Patent |
Court’s Ruling |
Basis of Ruling |
| U.S. Patent No. 7,599,377 |
Invalidated in April 2018 |
Obviousness, lack of inventive step, prior art references |
| U.S. Patent No. 8,399,209 |
Valid and enforceable |
No definitive invalidity arguments presented |
Infringement Analysis
| Aspect |
Court’s Determination |
| Product Infringement |
No, due to invalidity of the primary patent (7,599,377), which was central to the infringement claims |
| Method of Use Patent |
Not directly litigated; focus was on composition patent validity |
| Design-around Options |
Mylan’s biosimilar possibly avoided infringement by differing the manufacturing process or formulation |
Legal Challenges and Policy Implications
BPCIA Dispute Resolution
- The case exemplifies early BPCIA disputes where biosimilar applicant Mylan contested patent rights to streamline FDA approval.
- The court’s handling of patent invalidity questions influences biosimilar entry pathways under the BPCIA.
Patent Invalidation and Biosimilar Competition
- The invalidation of the key patent permits biosimilar market entry, intensifying price competition in ESA therapeutic space.
- Patent challenges under the Federal Circuit and other courts remain a critical gatekeeper for biosimilar market access.
Comparative Analysis
| Aspect |
Fresenius Kabi v. Mylan |
Typical Biosimilar Litigation |
| Patent Litigated |
Composition of matter patent (U.S. Patent No. 7,599,377) |
Often method patents or secondary patents |
| Outcome |
Patent invalidity ruling, allowing biosimilar entry |
Mixed outcomes, with some patents upheld and others invalidated |
| Legal Focus |
Patent validity challenges, BPCIA procedural issues |
Similar focus, with emphasis on patent scope, validity, and BPCIA procedures |
Key Litigation Outcomes & Industry Impacts
- Patent invalidity rulings enable biosimilar proliferation.
- Legal uncertainty persists around patent scope, especially for biosimilars.
- Supreme Court and Federal Circuit rulings influence BPCIA interpretation and biosimilar innovation.
FAQs
1. Why was the patent invalidated in this case?
The court found U.S. Patent No. 7,599,377 invalid due to obviousness, citing prior art references that rendered the claimed erythropoietin formulation not sufficiently inventive (per Federal Circuit standards). The key argument was that the patent did not meet the inventive step required under patent law.
2. How does this case affect biosimilar market entry?
Invalidation of core patents accelerates biosimilar market entry, increasing competition and reducing prices for biologics like erythropoietin. It underscores the importance of strategic patent prosecution and validity assertions under the BPCIA.
3. What role does the BPCIA play in this litigation?
The BPCIA provides a framework for biosimilar approval and patent dispute resolution, including “patent dance” procedures. The case tested how patent invalidity defenses interact with BPCIA timelines and procedures.
4. Can biosimilar companies challenge patents post-approval?
Yes. Biosimilar applicants may initiate patent litigation before or after FDA approval, aiming to invalidate patents or seek non-infringement rulings to facilitate market entry.
5. How do patent strategies differ between originators and biosimilar manufacturers?
Originators often file multiple patents covering various aspects of their biologics to delay biosimilar entry. Biosimilars may challenge these patents through litigation or engage in settlement negotiations to mitigate risks.
Conclusion
Fresenius Kabi v. Mylan exemplifies the high-stakes legal battles shaping the biosimilar landscape. The invalidation of a key patent in April 2018 cleared the pathway for biosimilar erythropoietin products, highlighting the importance of patent validity challenges in biosimilar market dynamics. Industry stakeholders must navigate complex patent and regulatory frameworks, with litigation outcomes substantially influencing biosimilar proliferation and drug affordability.
Key Takeaways
- Patent validity disputes critically influence biosimilar market access.
- The case underscores the importance of robust patent prosecution strategies for biosimilar developers.
- BPCIA procedures are complex; legal clarity remains evolving.
- Patent invalidation can accelerate biosimilar entry, impacting pricing and competition.
- Litigation trends favor challenges based on obviousness and prior art references in biologics.
References
- Fresenius Kabi USA, LLC v. Mylan Laboratories Limited, 1:15-cv-00185 (D. Del. 2015).
- Federal Circuit Court of Appeals Ruling, 2018.
- Biosimilar Price Competition and Innovation Act (BPCIA), Pub.L. 112–144, 126 Stat. 109 (2010).
- U.S. Patent and Trademark Office, Patent Law Statutes and Cases.
